Bioblast Announces Results of Trehalose Clinical Study
October 24, 2016 06:00 ET
|
Bioblast Pharma
Pharmacokinetic Study in Healthy Volunteers Demonstrated Trehalose to be Safe and Well Tolerated at Twice the Dose Levels Used in Prior Clinical Studies Results Support Weight-Based Dosing Paradigm...
Bioblast’s Special Medical Advisor to Make a Presentation Today On Trehalose as a Potential Therapeutic Agent for OPMD
September 26, 2016 08:00 ET
|
Bioblast Pharma
TEL AVIV, Israel, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced that Zohar Argov, MD,...
Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients
September 12, 2016 06:00 ET
|
Bioblast Pharma
TEL AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of the Extension...
Bioblast Pharma Announces Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016
September 07, 2016 08:00 ET
|
Bioblast Pharma
TEL AVIV, Israel, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced it will be featured as a...
Bioblast Pharma Reports Second Quarter 2016 Financial Results
August 25, 2016 08:00 ET
|
Bioblast Pharma
TEL AVIV, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Pharma Updates Corporate Plans
June 09, 2016 06:00 ET
|
Bioblast Pharma
Trehalose Phase 2b Trial in Oculopharyngeal Muscular Dystrophy (OPMD) On Track to Commence During the Second Half of 2016 Focus On Trehalose As a Potential Platform Corporate...
Bioblast Pharma Reports First Quarter 2016 Financial Results
May 25, 2016 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., May 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
BioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting
April 14, 2016 16:05 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., April 14, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will present previously announced positive...
BioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering
March 17, 2016 07:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., March 17, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN) (the "Company" or "ORPN") announced that it has entered into definitive securities purchase agreements...
BioBlast Pharma Announces Positive Final Results from HOPEMD Phase 2 Open-Label Clinical Study of Trehalose 90mg/mL IV Solution in Oculopharyngeal Muscular Dystrophy (OPMD)
March 16, 2016 08:00 ET
|
Bioblast Pharma Ltd.
NEW HAVEN, Conn., March 16, 2016 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD...